{
    "clinical_study": {
        "@rank": "40015", 
        "acronym": "BUFLU", 
        "brief_summary": {
            "textblock": "Analyze the results of conditioning with once-daily dose intravenous busulfan and\n      fludarabine in patients undergoing HLA identical sibling Allogeneic HSCT for myeloid\n      malignancies."
        }, 
        "brief_title": "Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloid Leukemia", 
            "Myelodysplastic Syndrome", 
            "Myeloproliferative Disorders", 
            "Chronic Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Myeloproliferative Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this study the investigators evaluate a conditioning regimen consisting in Fludarabine 40\n      mg/m2 once daily i.v in 60 min. on days -6 to -3 (total dose 160 mg/m2), followed by\n      Busulfan 3,2 mg/kg once daily i.v. in 180 min. in the same days (total dose 12,8 mg/kg). No\n      busulfan pharmacokinetic monitoring is performed. Graft versus host disease prophylaxis\n      consists in the combination of cyclosporine and methotrexate. Graft products obtained from\n      bone marrow or peripheral blood of HLA identical sibling donors are not manipulated in their\n      cellular content before transplantation. Blood products were leukocyte depleted and\n      irradiated before transfusion. Supportive care, including seizure prophylaxis, isolation\n      measures, antiemetics, antimicrobial agents and growth factors use are followed according to\n      standard procedures.\n\n      The main objectives are to record data regarding engraftment, regimen related toxicity and\n      outcome in different patient populations according to age, disease type, disease status at\n      HSCT and comorbidities."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acute Myeloid Leukemia\n\n          -  Myelodysplastic Syndrome\n\n          -  Myeloproliferative Disorders\n\n          -  Chronic Myeloid Leukemia\n\n        Exclusion Criteria:\n\n          -  Performance status ECOG>2\n\n          -  Cardiomyopathy (LVEF <39%)\n\n          -  Pulmonary dysfunction (DLCO<39%)\n\n          -  Hepatic dysfunction Grade >1\n\n          -  Renal dysfunction Grade >1 (Creatinine > 1.6 mg/dl)\n\n          -  HIV infection\n\n          -  Other active neoplasm"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adults with myeloid malignancies submitted to allogeneic HSCT with an HLA identical\n        sibling donor"
            }
        }, 
        "enrollment": {
            "#text": "143", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01683123", 
            "org_study_id": "get-buf-2010-02"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Busulfan", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Allogeneic HSCT", 
            "Busulfan", 
            "Fludarabina"
        ], 
        "lastchanged_date": "September 10, 2012", 
        "number_of_groups": "1", 
        "official_title": "Phase 2 Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning For HLA Identical Sibling Allogeneic HSCT In Myeloid Malignancies. Retrospective Analysis.", 
        "overall_official": [
            {
                "affiliation": "Grupo Espanol de trasplantes hematopoyeticos y terapia celular", 
                "last_name": "Javier De la Serna, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Grupo Espanol de trasplantes hematopoyeticos y terapia celular", 
                "last_name": "Guillermo Sanz, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Ministry of Health and Consumption", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01683123"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Grupo Espanol de trasplantes hematopoyeticos y terapia celular", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Grupo Espanol de trasplantes hematopoyeticos y terapia celular", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2007", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "September 2012"
    }
}